Neuland Laboratories reported a strong performance for the financial year ending March 31, 2026, with revenue reaching ₹2,022.98 crore. The company has recommended a final dividend of ₹34 per share (340%) and announced a ₹143.4 crore investment to expand its manufacturing capacity at Unit 1 by 120.5 KL to meet growing global demand. Additionally, the Board appointed Dr. Mauricio Futran as an Additional Director.
Annual Financial Highlights
Neuland Laboratories delivered robust growth in the fiscal year ended March 31, 2026. The company reported annual revenue from operations of ₹2,022.98 crore, compared to ₹1,476.84 crore in the previous year. Profit for the year saw a significant increase, standing at ₹363.99 crore, up from ₹260.11 crore in FY2025. This performance reflects the company’s sustained momentum in its core operations.
Dividend Recommendation
Reflecting the company’s positive financial health, the Board of Directors has recommended a final dividend of ₹34 per equity share (representing 340%) on a face value of ₹10 each for the financial year 2025-26. The dividend is subject to approval by the shareholders at the upcoming 42nd Annual General Meeting scheduled for August 4, 2026.
Manufacturing Capacity Expansion
To support its long-term growth strategy, Neuland Laboratories is set to expand its production capacity at Unit 1 in Telangana. The company plans a capital investment of ₹143.4 crore (inclusive of GST) to add 120.5 KL to its existing 256 KL capacity. With the current utilization rate at 91%, this expansion is designed to maintain efficiency and cater to the rising demand from customers. The project is expected to be completed within 12 to 18 months and will be funded through a mix of internal accruals and borrowings.
Board Appointment
The company also announced the appointment of Dr. Mauricio Futran as an Additional Director in the capacity of Non-Executive Non-Independent Director, effective May 12, 2026. Dr. Futran brings over 40 years of experience in process and product development and manufacturing from his tenure at global pharmaceutical leaders like Merck & Co, Bristol-Myers Squibb, and Johnson & Johnson.
Source: BSE
